Abstract 2208
Background
There is limited information on the association among complementary medicin (CM), toxicities and overall survival of patients with cancer who receive CM compared with those who do not.
Methods
This is a prospective study including 223 patients collected during 6 months between July 15, 2018 and January 15, 2019 in the department of medical oncology at the Habib Bourguiba university Hospital. All patients were questioned about the concept of taking herbs and botanicals such as gravila and Alinda. We analyzed the demographic data, the toxicities after the consumption of plants as well as the causal link. Then we compared overall survival among those who receive plants versus the non-users.
Results
The average age was 53 years (2-86 years old). There were 152 women and 71 men. 83 patients were illiterate (37.2%). 110 patients had breast cancer (49.3%), the others included colorectal, endometrial, cervical, gastric, ovarian, lung, bladder and head and neck cancers). 97 had metastatic disease (43.4%). 97 patients had taken plants (43.4%), during the medical treatment in 57 cases (58.7%). 60 patients had consumed Alinda (61.8%) and 36 patients had received Graviola (37.1%). 62 women had taken plants against 37 men (χ2 = 1.425, ddl = 1, α = 5%, p = 0.147). 49 patients with metastatic disease had taken plants against 48 with localized cancer (χ2 = 3.468, ddl = 2, α = 5%, p = 0.177). 10 patients have had diarrhea (10.3%), 10 cytolysis (10.3%), 11 cholestasis (11.3%), 15 thrombocytosis (15.4%), 17 leukocytosis (17.5%) and 13 anemia (13.4%). Only leukocytosis, thrombocytosis, and diarrhea were related to plant consumption with p = 0.0001, p = 0.016 and p = 0.014 respectively. Overall survival at 5 years was 67.1%. It was lower in patients consuming the plants (54% vs 83% p = 0.023).
Conclusions
The consumption of Graviola and Alinda was associated with a decrease in the 5 years overall survival (p = 0.023). It was associated with leukocytosis, thrombocytosis, and diarrhoea. This consumption was not statistically different between men and women nor between the localized or metastatic stage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract
6068 - Study of Photodynamic therapy in vitro
Presenter: Irene Jiménez Munguía
Session: Poster Display session 1
Resources:
Abstract
3011 - The potential of neratinib plus dasatinib in overcoming and preventing neratinib resistance in HER2-positive breast cancer models
Presenter: Neil Conlon
Session: Poster Display session 1
Resources:
Abstract
2644 - Novel HDACi, MHY446, induces apoptosis via regulation of mitochondria-endoplasmic reticulum interaction in HCT116 human colorectal cancer cells
Presenter: Nam Deuk Kim
Session: Poster Display session 1
Resources:
Abstract
3085 - Dual inhibition of TGF-β and AXL as a novel treatment for colorectal cancer
Presenter: Davide Ciardiello
Session: Poster Display session 1
Resources:
Abstract
1314 - PARP inhibition enhances cisplatin sensitivity in cervical cancer by modulating β-catenin signaling
Presenter: Minakshi Mann
Session: Poster Display session 1
Resources:
Abstract
2417 - Synergistic effect of DSF combined treatment with cisplatin in atypical teratoid/rhabdoid tumors (AT/RT)
Presenter: Seung Ah Choi
Session: Poster Display session 1
Resources:
Abstract
1149 - Reactive oxygen species induced by OSU-A9 inhibit the growth of duodenal cancer and gastric cancer cells through dephosphorylating intranuclear pyruvate kinase muscle isozyme M2
Presenter: Li-Yuan Bai
Session: Poster Display session 1
Resources:
Abstract
1862 - New therapy for intrahepatic cholangiocarcinoma targeted to cancer associated fibroblasts
Presenter: Takahiro Yamanaka
Session: Poster Display session 1
Resources:
Abstract
782 - Macrophage-cancer cell fusion is mediated by Phosphatidylserine-CD36 receptor interaction and induced by ionizing radiation
Presenter: Ivan Shabo
Session: Poster Display session 1
Resources:
Abstract